

## Commercial/Healthcare Exchange PA Criteria Effective: November 13, 2019

**Prior Authorization:** Triptan Nasal Sprays

**Products Affected:** Tosymra (sumatriptan) Nasal Spray, Zomig (zolmitriptan) nasal spray

### **Medication Description:**

The “triptans” are 5HT-1B/1D receptor agonists used to treat acute migraine and acute cluster headaches. These drugs are used to effectively and quickly relieve headache pain, sensitivity to light and noise, and nausea and vomiting associated with migraines. The triptans have varying onset and durations of action. A non-oral formulation, such as a nasal spray or injection, is recommended for patients with severe nausea and vomiting, those who awaken with a migraine, or those with a rapid escalation of pain intensity. Two triptans (sumatriptan, zolmitriptan) are marketed as nasal sprays.

### **Covered Uses:**

Tosymra: Acute treatment of migraine with or without aura in adults

Zolmitriptan: Acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older

### **Exclusion Criteria:**

1. Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina
2. Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
3. History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke
4. Peripheral vascular disease
5. Ischemic bowel disease
6. Uncontrolled hypertension
7. Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine<sub>1</sub> (5-HT<sub>1</sub>) agonist
8. Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor
9. Hypersensitivity to sumatriptan
10. Severe hepatic impairment

### **Required Medical Information:**

1. Diagnosis
2. Previous medications tried and failed

### **Age Restrictions:**

Zolmitriptan: 12 years of age and older

Tosymra: 18 years of age and older

**Prescriber Restriction:** None

**Coverage Duration:** 12 months

**Other Criteria:**

- A. The member has a diagnosis of acute treatment of migraine with or without aura; **AND**
- B. The member has a history of failure of TWO of the following generic oral triptan agents: almotriptan, naratriptan, rizatriptan, sumatriptan succinate, zolmitriptan ODT, zolmitriptan, eletriptan, or frovatriptan; **AND**
- C. The member has a history of failure of Zolmitriptan nasal spray.

**References:**

1. Tosymra (sumatriptan nasal spray) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; July 2019.
2. Zomig nasal spray (zolmitriptan) [prescribing information]. Bridgewater, NJ: Amneal Specialty, a division of Amneal Pharmaceuticals LLC; April 2019.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/13/2019
2	Update	Renamed policy from Tosymra to Triptan nasal spray Added zolmitriptan indication and age restrictions Added Zolmitriptan nasal spray to products affected	Prior Authorization Covered uses Age restrictions Products affected	2/9/2021
3	Update	Add Brand name Zomig as an Affected Product Removed the Step through brand Zomig nasal spray, changed to step through generic zolmitriptan	Affected Products Other Criteria	11/29/2022

Last Review Date: November 2022



Confidential Information

This document is confidential and proprietary to Emblemhealth. Unauthorized use and distribution are prohibited.